Lumos Diagnostics (ASX:LDX) has released its quarterly report for the period ending 31 March 2025.
Key Highlights from the quarter include:
- Revenue of US$3.5 million for the quarter, up 21% compared to the prior quarter (Q2 FY25).
- Product revenue was up 17% on Q2 and Services revenue was up 22% on Q2 FY25.
- Total YTD revenue is US$9.8 million at quarter’s end, up 44% compared to the prior year.
- Additional FebriDx® distribution partnership agreements completed in the U.S. with MedPro Associates and the US Defense Logistics Agency (DLA).
- FebriDx CLIA Waiver Study continues with around 351 patients tested to-date, including 37 bacterial-positive patients. Study completion and FDA application anticipated in 2H CY2025.
- Hologic fFN project scope of work expansion signed and expected to generate an additional US$0.6-US$0.8 million in fee revenue.
